Epidermolysis Bullosa — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
In vivo confocal microscopic evaluation of patients with epidermolysis bullosa demonstrates severe loss of corneal nerves.
Saricay Leyla Yavuz et al. — American journal of ophthalmology case reports (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41716620/
- 2.
The tumor microenvironment of cutaneous squamous cell carcinoma in high-risk patient groups: A scoping review.
Wang Wandong et al. — JID innovations : skin science from molecules to population health (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41815791/
- 3.
Developing CRISPR-Based Therapies for Epidermolysis Bullosa: A Comprehensive Review of Current Strategies.
du Rand Alex et al. — Drugs (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41731282/
- 4.
Deciphering MAPK dependence in epidermolysis bullosa-associated squamous cell carcinoma: Toward biomarker-guided MEK inhibition.
Qin Jiuyuan et al. — The Journal of investigative dermatology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41718523/
- 5.
Meta-Analysis of Pain Management in Epidermolysis Bullosa.
Puttinger Christian et al. — The British journal of dermatology (23 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41866785/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Recruiting — Phase 2 — TWi Biotechnology, Inc.
https://clinicaltrials.gov/study/NCT06073132
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Epidermolysis Bullosa
Epidermolysis bullosa is a group of rare genetic conditions that cause extremely fragile skin that blisters and tears easily. It affects the proteins that anchor skin layers together. Severity ranges from mild to life-threatening. Gene therapy and advanced wound care are transforming treatment.
Most Recent Research
PURPOSE: Epidermolysis bullosa (EB) is a rare inherited genetic disorder associated with severe ocular surface complications and progressive corneal scarring. This case series aimed to structurally characterize and quantitatively analyze central corneal subbasal nerve plexus loss using in vivo confocal microscopy (IVCM) in pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). OBSERVATIONS: This retrospective case series included five pediatric patients with RDEB presenting with ocular and systemic manifestations. In vivo confocal microscopy (IVCM) imaging showed severe central subbasal corneal nerve plexus loss in 85% of eyes, with a median total nerve density of 0 μm/mm2 (IQR: 0-5150.67), main nerve trunk density of 0 μm/mm2 (IQR: 0-2720.56), and branch nerve density of 0 μm/mm2 (IQR: 0-2769.22). Dendritiform reflective structures were qualitatively observed in multiple scans of eyes demonstrating marked central subbasal nerve loss.No immunophenotyping was performed. Corneal sensation testing was not performed due to severe ocular surface fragility and photophobia; therefore, no clinical diagnosis or staging of NK was inferred or concluded from this cohort. CONCLUSIONS AND IMPORTANCE: This series identifies profound structural corneal denervation of the central subbasal plexus on IVCM in pediatric RDEB-associated ocular surface disease. The findings support future prospective studies investigating corneal nerve-regeneration and epithelial-stabilization frameworks to preserve long-term visual outcomes in children with RDEB.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.